Clinical models to predict response and survival in metastatic melanoma (MM) patients (pts) treated with anti-PD-1 alone (PD1) or combined with ipilimumab (IPI+PD1).-MedSci.cn

Clinical models to predict response and survival in metastatic melanoma (MM) patients (pts) treated with anti-PD-1 alone (PD1) or combined with ipilimumab (IPI+PD1).

Da Silva, IEDP; Ahmed, T; Lo, S; Rai, R; Smith, JL; Park, JJ; Nabhan, C; Scolyer, RA; Carlino, MS; McQuade, JL; Johnson, DB; Long, GV; Menzies, AM

JOURNAL OF CLINICAL ONCOLOGY, 2019; 37 (15):

科室
- - 订阅+
  - 更多科室
工具
服务